Financial insights of DNLI

MyFinsight

For the quarter ending 2025-09-30, DNLI made $148,128,000 in revenue. -$126,740,000 in net income. Net profit margin of -85.56%.

Unit: Dollar

Income Statement	2025-09-30	2025-06-30	2024-09-30	2024-06-30
Research and development	101,950,000	102,696,000	98,238,000	91,399,000
Total collaboration revenue	-	-	-	0
General and administrative	35,484,000	32,267,000	24,949,000	25,194,000
Total operating expenses	137,434,000	134,963,000	123,187,000	116,593,000
Gain from divestiture of small molecule programs	0	0	-	0
Loss from operations	-137,434,000	-134,963,000	-123,187,000	-116,593,000
Interest and other income, net	10,532,000	10,844,000	15,995,000	17,567,000
Net loss	-126,902,000	-124,119,000	-107,192,000	-99,026,000
Net unrealized gain (loss) on marketable securities, net of tax	162,000	-1,098,000	8,188,000	-1,363,000
Comprehensive loss	-126,740,000	-125,217,000	-99,004,000	-100,389,000

Net loss per share, basic (usd per share)	-0.74	-0.72	-0.63	-0.59
Net loss per share, diluted (usd per share)	-0.74	-0.72	-0.63	-0.59
Weighted average number of shares outstanding, basic (in shares)	172,421,492	171,449,847	169,456,988	168,831,329
Weighted average number of shares outstanding, diluted (in shares)	172,421,492	171,449,847	169,456,988	168,831,329